PL1612203T3 - Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu - Google Patents

Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu

Info

Publication number
PL1612203T3
PL1612203T3 PL04015091T PL04015091T PL1612203T3 PL 1612203 T3 PL1612203 T3 PL 1612203T3 PL 04015091 T PL04015091 T PL 04015091T PL 04015091 T PL04015091 T PL 04015091T PL 1612203 T3 PL1612203 T3 PL 1612203T3
Authority
PL
Poland
Prior art keywords
methylpropyl
dimethylamino
ethyl
crystalline forms
phenol hydrochloride
Prior art date
Application number
PL04015091T
Other languages
English (en)
Inventor
Andreas Fischer
Helmut Buschmann
Michael Gruss
Dagmar Lischke
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1612203(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL1612203T3 publication Critical patent/PL1612203T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
PL04015091T 2004-06-28 2004-06-28 Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu PL1612203T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (1)

Publication Number Publication Date
PL1612203T3 true PL1612203T3 (pl) 2007-12-31

Family

ID=34925507

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04015091T PL1612203T3 (pl) 2004-06-28 2004-06-28 Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu
PL05770026T PL1799633T3 (pl) 2004-06-28 2005-06-27 Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL05770026T PL1799633T3 (pl) 2004-06-28 2005-06-27 Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych

Country Status (27)

Country Link
US (16) US20070213405A1 (pl)
EP (2) EP1612203B1 (pl)
JP (1) JP4990764B2 (pl)
KR (1) KR101096501B1 (pl)
CN (1) CN1997621B (pl)
AR (2) AR049949A1 (pl)
AT (2) ATE368639T1 (pl)
AU (1) AU2005256512B2 (pl)
BR (2) BR122018014454B8 (pl)
CA (1) CA2572147C (pl)
CY (2) CY1106929T1 (pl)
DE (2) DE602004007905T2 (pl)
DK (2) DK1612203T3 (pl)
EC (1) ECSP17046065A (pl)
ES (2) ES2291780T3 (pl)
HR (1) HRP20110050T8 (pl)
IL (1) IL180373A (pl)
MX (1) MXPA06014741A (pl)
NO (3) NO338605B1 (pl)
NZ (1) NZ551605A (pl)
PE (1) PE20060372A1 (pl)
PL (2) PL1612203T3 (pl)
PT (2) PT1612203E (pl)
RU (1) RU2423345C2 (pl)
SI (2) SI1612203T1 (pl)
WO (1) WO2006000441A2 (pl)
ZA (1) ZA200700774B (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
EP1612203B1 (en) * 2004-06-28 2007-08-01 Grünenthal GmbH Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
HUE047275T2 (hu) 2007-12-07 2020-04-28 Gruenenthal Gmbh (1R,2R)-3-(3-dimetil-amino-1-etil-2-metil-propil)-fenol kristályos módosításait tartalmazó gyógyszerek
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
AR077493A1 (es) 2009-07-22 2011-08-31 Gruenenthal Gmbh Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
US20130116333A1 (en) 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
DK3650439T3 (da) 2010-07-23 2021-03-08 Gruenenthal Gmbh Salte eller co-krystaller af 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
PL2680832T3 (pl) 2011-03-04 2020-03-31 Grünenthal GmbH Wodna formulacja farmaceutyczna tapentadolu do podawania doustnego
CA2828637C (en) 2011-03-04 2019-06-11 Grunenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
EA024193B1 (ru) * 2011-03-04 2016-08-31 Грюненталь Гмбх Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
NO2736497T3 (pl) 2011-07-29 2018-01-20
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
SI3273953T1 (sl) 2015-03-27 2019-03-29 Gruenenthal Gmbh Stabilna oblika za parenteralno dovajanje tapentadola
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
ES2772806T3 (es) 2016-04-19 2020-07-08 Ratiopharm Gmbh Fosfato de tapentadol cristalino
WO2018055070A1 (en) 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
WO2022098644A1 (en) 2020-11-03 2022-05-12 Landos Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
GEP20022636B (en) * 1996-08-14 2002-02-25 Searle & Co Us 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
JP4180368B2 (ja) * 2000-10-31 2008-11-12 サンド・アクチエンゲゼルシヤフト 塩酸ベンラファキシンの結晶形
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
KR100874952B1 (ko) * 2001-09-13 2008-12-19 깃세이 야쿠힌 고교 가부시키가이샤 히드록시노르에페드린 유도체 염산염의 결정
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
EP1612203B1 (en) * 2004-06-28 2007-08-01 Grünenthal GmbH Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Also Published As

Publication number Publication date
EP1612203A1 (en) 2006-01-04
DK1799633T3 (da) 2011-03-28
AR116052A2 (es) 2021-03-25
IL180373A (en) 2012-05-31
NO338605B1 (no) 2016-09-12
NZ551605A (en) 2010-01-29
CN1997621B (zh) 2011-06-15
US20230174458A1 (en) 2023-06-08
PL1799633T3 (pl) 2011-06-30
US20200102261A1 (en) 2020-04-02
NO20070162L (no) 2007-01-24
US20190062263A1 (en) 2019-02-28
CY1106929T1 (el) 2012-09-26
AR049949A1 (es) 2006-09-20
CY1111530T1 (el) 2015-08-05
US20070213405A1 (en) 2007-09-13
US20210261492A1 (en) 2021-08-26
BR122018014454B8 (pt) 2021-07-27
EP1612203B1 (en) 2007-08-01
BR122018014454B1 (pt) 2019-09-03
DE602004007905D1 (de) 2007-09-13
US20200385334A1 (en) 2020-12-10
HRP20110050T8 (en) 2011-03-31
PE20060372A1 (es) 2006-05-08
MXPA06014741A (es) 2007-02-12
SI1799633T1 (sl) 2011-05-31
CN1997621A (zh) 2007-07-11
DK1612203T3 (da) 2007-12-03
SI1612203T1 (sl) 2007-12-31
ATE368639T1 (de) 2007-08-15
WO2006000441A3 (en) 2006-05-04
ATE496021T1 (de) 2011-02-15
WO2006000441A2 (en) 2006-01-05
US20180029976A1 (en) 2018-02-01
KR101096501B1 (ko) 2011-12-20
ECSP17046065A (es) 2018-11-30
EP1799633A2 (en) 2007-06-27
PT1612203E (pt) 2007-08-20
RU2423345C2 (ru) 2011-07-10
RU2007103297A (ru) 2008-08-10
US20100160447A1 (en) 2010-06-24
AU2005256512B2 (en) 2011-05-19
IL180373A0 (en) 2007-06-03
US20180230082A1 (en) 2018-08-16
NO341239B1 (no) 2017-09-25
US20160122287A1 (en) 2016-05-05
ES2291780T3 (es) 2008-03-01
US20090186947A1 (en) 2009-07-23
AU2005256512A1 (en) 2006-01-05
PT1799633E (pt) 2011-03-07
EP1799633B1 (en) 2011-01-19
US20140296346A1 (en) 2014-10-02
NO20171103A1 (no) 2007-01-24
US7994364B2 (en) 2011-08-09
NO20160914A1 (no) 2007-01-24
ES2359504T3 (es) 2011-05-24
US20170166515A1 (en) 2017-06-15
BRPI0512792A (pt) 2008-04-08
CA2572147A1 (en) 2006-01-05
KR20070039929A (ko) 2007-04-13
ZA200700774B (en) 2008-09-25
US20120302643A1 (en) 2012-11-29
HRP20110050T1 (hr) 2011-02-28
JP2008504326A (ja) 2008-02-14
NO343922B1 (no) 2019-07-08
CA2572147C (en) 2012-10-30
DE602004007905T2 (de) 2008-05-08
US20140011886A1 (en) 2014-01-09
US20110294898A1 (en) 2011-12-01
DE602005026031D1 (de) 2011-03-03
JP4990764B2 (ja) 2012-08-01

Similar Documents

Publication Publication Date Title
IL180373A0 (en) Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
IL255201B (en) Process for preparing (r2, 1r)-3-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DK1786403T3 (da) Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
IL237478A0 (en) Crystalline changes of (32)-3-(r1,r-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
IL186220A0 (en) Processes for the preparation of atomoxetine hydrochloride
IL179328A0 (en) Levalbuterol hydrochloride polymorph b
IL187735A0 (en) 2-(n-nethyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
EP1778208A4 (en) VENLAFAXINE-HYDROCHLORIDE-CONTAINING CAPSULES WITH EXTENDED RELEASE
EP1802575A4 (en) POLYMORPH OF N, N-DIETHYL-4- (3-FLUORPHENYLPIPERIDIN-4-YLIDENETHYL) -BENZAMIDE HYDROCHLORIDE SALT